Carfilzomib + Sotorasib for Lung Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop chemotherapy, immunotherapy, radiation therapy, KRAS inhibitors, and investigational therapies for a certain period before starting the trial. However, the protocol does not specify about other medications, so it's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug combination Carfilzomib and Sotorasib for lung cancer?
Sotorasib has shown promising anticancer activity in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), with a clinically relevant response rate and duration observed in clinical trials. It is approved for use in patients with this specific mutation who have been previously treated, indicating its effectiveness in this context.12345
Is the combination of Carfilzomib and Sotorasib safe for humans?
Sotorasib, also known as Lumakras, has been approved for use in certain lung cancer patients and has a manageable safety profile, with common side effects including diarrhea, muscle pain, nausea, fatigue, liver issues, and cough. However, specific safety data for the combination of Carfilzomib and Sotorasib is not available in the provided research.23456
What makes the drug combination of Carfilzomib and Sotorasib unique for lung cancer treatment?
What is the purpose of this trial?
This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Carfilzomib is a drug that binds to and inhibits the activity of the protein complex that is responsible for degrading other damaged or unneeded proteins. The inhibition of this protein by carfilzomib can then cause tumor growth inhibition and cell death. Sotorasib is a drug that binds to and inhibits the activity of the KRAS G12C mutant. This may inhibit growth in KRAS G12C-expressing tumor cells. Combining carfilzomib and sotorasib may be a safe and effective treatment option for patients with KRAS G12C-mutated advanced or metastatic NSCLC.
Research Team
Jyoti Malhotra, MD
Principal Investigator
City of Hope Medical Center
Ravi Salgia
Principal Investigator
City of Hope Medical Center
Eligibility Criteria
This trial is for adults with advanced or metastatic non-small cell lung cancer that has a specific mutation called KRAS G12C. Participants should have measurable disease and may have had prior treatments, but there are certain criteria they must meet to join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive carfilzomib IV and sotorasib PO in 28-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Optional Biopsy
Participants may undergo optional biopsies on study
Treatment Details
Interventions
- Carfilzomib
- Sotorasib
Carfilzomib is already approved in United States, European Union, Canada, Japan for the following indications:
- Multiple myeloma
- Multiple myeloma
- Multiple myeloma
- Multiple myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator